- Home
- CNNE vs RCUS Comparison
CNNE vs RCUS Comparison
Compare CNNE & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNNE
- RCUS
- Stock Information
- Founded
- CNNE 2014
- RCUS 2015
- Country
- CNNE United States
- RCUS United States
- Employees
- CNNE N/A
- RCUS N/A
- Industry
- CNNE Restaurants
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- CNNE Consumer Discretionary
- RCUS Health Care
- Exchange
- CNNE Nasdaq
- RCUS Nasdaq
- Market Cap
- CNNE 1.1B
- RCUS 1.2B
- IPO Year
- CNNE N/A
- RCUS 2018
- Fundamental
- Price
- CNNE $18.35
- RCUS $16.96
- Analyst Decision
- CNNE Buy
- RCUS Buy
- Analyst Count
- CNNE 3
- RCUS 8
- Target Price
- CNNE $23.33
- RCUS $26.50
- AVG Volume (30 Days)
- CNNE 580.5K
- RCUS 1.2M
- Earning Date
- CNNE 11-11-2025
- RCUS 11-05-2025
- Dividend Yield
- CNNE 3.21%
- RCUS N/A
- EPS Growth
- CNNE N/A
- RCUS N/A
- EPS
- CNNE N/A
- RCUS N/A
- Revenue
- CNNE $437,200,000.00
- RCUS $262,000,000.00
- Revenue This Year
- CNNE N/A
- RCUS N/A
- Revenue Next Year
- CNNE N/A
- RCUS N/A
- P/E Ratio
- CNNE N/A
- RCUS N/A
- Revenue Growth
- CNNE N/A
- RCUS 6.07
- 52 Week Low
- CNNE $15.92
- RCUS $6.50
- 52 Week High
- CNNE $22.36
- RCUS $18.98
- Technical
- Relative Strength Index (RSI)
- CNNE 46.05
- RCUS 63.28
- Support Level
- CNNE $18.08
- RCUS $16.04
- Resistance Level
- CNNE $18.87
- RCUS $18.42
- Average True Range (ATR)
- CNNE 0.43
- RCUS 1.30
- MACD
- CNNE 0.03
- RCUS 0.15
- Stochastic Oscillator
- CNNE 30.85
- RCUS 69.39
About CNNE Cannae Holdings Inc.
Cannae Holdings Inc is a holding company that manages and operates a group of companies and investments. The company's reportable segments are Restaurant Group, Dun & Bradstreet, Alight, BKFC, Corporate and Other. Majority of the company's revenue is generated from its Restaurant Group segment which represents the operations of O'Charley's and Ninety Nine Restaurants.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.